Money moves in silence. Download 2025 State of Venture Report: a data-driven analysis of active funds, unicorn, and family offices
About usSign in

Angelini Ventures

WebsiteLinkedIncbCrunchbase
Status
ACTIVE
Global HQ
Rome, Italy
Countries of investment
  • United States
  • Denmark
  • France
  • Italy
  • Switzerland
  • Canada
  • Singapore
  • Austria
  • Germany
  • Spain
  • Portugal
  • Poland
  • Czech Republic
  • Slovakia
  • Hungary
  • Romania
  • Bulgaria
  • Greece
  • Turkey
  • Sweden
  • Holland
  • Russia
  • United Kingdom
  • Belgium
  • Ireland
Investment stages
  • Seed
  • Series A
  • Series B
  • Series C
Industries
  • Digital Health
  • Biotech
  • Medtech
  • Life Sciences
  • Healthcare Innovation
About
Angelini Ventures is committed to advancing the future of global healthcare through investments in digital health, biotechnology, and medtech. Leveraging the heritage and domain expertise of the Angelini Group, the firm supports visionary founders developing transformative solutions that improve patient outcomes and modernize healthcare systems.
Min check size
$582K
Max check size
$11.6M
Fund size
NPS

Investment Thesis

Angelini Ventures invests in transformative health and life-science innovations, focusing on digital health, biotech, and medtech. The firm backs founders developing solutions that advance patient care, therapeutics, and global healthcare systems.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

The team has deep expertise in life sciences, digital health, and healthcare innovation, backed by years of operational leadership within the Angelini Group. Their background includes biotech commercialization, clinical innovation, venture building, and strategic investments in global health.

Angelini Ventures Contacts Information

Primary contact

Secondary contact

Team

Paolo Di Giorgio – CEO & Managing Director; Elia Stupka – Managing Director; Tanja Dowe – Managing Director; Regina Hodits – Managing Director; Gabriela Manrique – Partner; Fabrizio Calisti – Medical Director; Thomas Thestrup – Senior Principal; Nils Bottler – Principal; Cesar Montero – Finance Manager; Barbara Saulini – Executive Assistant; Natasa Ralevic – Data Scientist; Martina Palmese – Communications Coordinator; Maya Misra – Senior Analyst; Lola Buono – Senior Associate; Sarah Fox – Senior Associate; Daniel Bode – Associate

Portfolio

Nuclidium

Elkedonia

TheriniBio

Nuevocor

nobi

Vantis

NEUmiRNA

Nouscom

Avation Medical

Cour

Noctrix

Freya

Cadence Neuroscience

Serenis

Arclight Therapeutics

Damona Pharmaceuticals

Congruence

GenEp

Pretzel Therapeutics

Extend (venture studio)

Argobio (venture studio)

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp